Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CPI-169

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

EZH2 inhibitor

Related drugs:

EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D